

Rat Anti-Mouse IL-10R (CD210) Monoclonal antibody, clone 1B1.3A (CABT-L4330)

This product is for research use only and is not intended for diagnostic use.

PRODUCT INFORMATION

| Product Overview | The 1B1.3A monoclonal antibody reacts with mouse IL-10R (IL-10 receptor) also known as CD210. The IL-10R is a class II cytokine receptor and is expressed by a variety of cell types including thymocytes, T lymphocytes, B lymphocytes, NK cells, monocytes, and macrophages. Upon binding IL-10, IL-10R stimulation results in many pleiotropic, effects in immunoregulation and inflammation. |
|--------------------|--|
| Target | Mouse IL-10R (CD210) |
| Immunogen | Recombinant ligand-binding domain of mouse IL-10R |
| Isotype | lgG1, κ |
| Source/Host | Rat |
| Species Reactivity | Mouse |
| Clone | 1B1.3A |
| Purification | Protein G purified. Purity>95%. Determined by SDS-PAGE |
| Conjugate | Functional Grade |
| Applications | in vivo blocking of IL-10/IL-10R signaling, in vitro blocking of IL-10R signaling, FC, WB |
| Molecular Weight | 150 kDa |
| Format | 0.2 μ M filtered liquid. Purified from tissue culture supernatant in an animal free facility |
| Concentration | Lot specific |

45-1 Ramsey Road, Shirley, NY 11967, USA

Tel: 1-631-624-4882 Fax: 1-631-938-8221

| Size | 5 mg |
|--------------|---|
| Buffer | PBS + 0.01% Tween, pH 6.5. Contains no stabilizers or preservatives. [low endotoxin azide- free] |
| | Endotoxin level: <2EU/mg (<0.002EU/μg). Determined by LAL gel clotting assay Related dilution buffer: CABT-LB02T, CABT-LB02 |
| Preservative | None |
| Storage | The antibody solution should be stored undiluted at 4°C, and protected from prolonged exposure to light. Do not freeze. |
| Ship | Wet ice |

BACKGROUND

| Introduction | The 1B1.3A monoclonal antibody reacts with mouse IL-10R (IL-10 receptor) also known as CD210. The IL-10R is a class II cytokine receptor and is expressed by a variety of cell types including thymocytes, T lymphocytes, B lymphocytes, NK cells, monocytes, and macrophages. Upon binding IL-10, IL-10R stimulation results in many pleiotropic, effects in immunoregulation and inflammation. IL-10R downregulates the expression of pro-inflammatory cytokines, MHC class II antigens, and co-stimulatory molecules on macrophages. It also enhances B lymphocyte survival, proliferation, and antibody production. IL-10R signaling can block NF-κB activity, and is involved in the regulation of the JAK-STAT signaling pathway. The 1B1.3A antibody is a neutralizing antibody and has been shown to block the binding of human IL-10, which cross-reacts with the mouse IL-10R. However, this clone does not recognize the human IL-10R. |
|--------------|---|
| Keywords | IL10RA;interleukin 10 receptor, alpha;II10r;CDw210;CDw210a;mIL-10R;AW553859;interleukin- 10 receptor subunit alpha;IL-10R1;IL-10RA;IL-10R subunit 1;IL-10R subunit alpha;IL-10 receptor subunit alpha;interleukin-10 receptor subunit 1; |

GENE INFORMATION

| Official Symbol | interleukin 10 receptor, alpha |
|-----------------|--|
| Synonyms | IL10RA; interleukin 10 receptor, alpha; II10r; CDw210; CDw210a; mIL-10R; AW553859; interleukin-10 receptor subunit alpha; IL-10R1; IL-10RA; IL-10R subunit 1; IL-10R subunit alpha; IL-10R subunit 1; IL-10R subunit alpha; interleukin-10 receptor subunit 1; |
| References | Burrack, K. S., et al. (2018). "Interleukin-15 Complex Treatment Protects Mice from Cerebral Malaria by Inducing Interleukin-10-Producing Natural Killer Cells." Immunity 48(4): 760-772 e764. PubMed;Verhagen, J. and D. C. Wraith (2014). "Blockade of LFA-1 augments in vitro |

differentiation of antigen-induced Foxp3(+) Treg cells." J Immunol Methods 414: 58-64. PubMed;Hu, Z., et al. (2013). "Regulatory CD8+ T cells associated with erosion of immune surveillance in persistent virus infection suppress in vitro and have a reversible proliferative defect." J Immunol 191(1): 312-322. PubMed;Mishra, P. K., et al. (2013). "Prevention of type 1 diabetes through infection with an intestinal nematode parasite requires IL-10 in the absence of a Th2-type response." Mucosal Immunol 6(2): 297-308. PubMed;Richter, K. and A. Oxenius (2013). "Non-neutralizing antibodies protect from chronic LCMV infection independently of activating FcgammaR or complement." Eur J Immunol 43(9): 2349-2360. PubMed